Polymeropoulos Mihael Hristos's Form 4 filing
Vanda Pharmaceuticals Inc. (VNDA) · filed Mar 4, 2025
- Accession no.
- 0000950170-25-032276
- Filed
- Mar 4, 2025
- Trade date
- Mar 1-3, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $47.1K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Polymeropoulos Mihael HristosCIK 0001355537 | Director, Officer (President and CEO), Other: Chairman of the Board |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2025 | Common Stock | FTax withholdingDisposed | −95,999 | $4.76 | −$456,955.24 | 2,265,731 | Direct | |
| Mar 3, 2025 | Common Stock | PPurchaseAcquired | +10,000 | $4.71 | +$47,100 | 2,275,731 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.